Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-2.28% $11.15
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 559.20 mill |
EPS: | -3.74 |
P/E: | -2.98 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 50.15 mill |
Avg Daily Volume: | 0.367 mill |
RATING 2024-03-28 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.98 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.51x |
Company: PE -2.98 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.121 (-98.91%) $-11.03 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 9.98 - 12.36 ( +/- 10.68%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-14 | Lettmann Jason | Buy | 4 400 | Common Stock |
2024-02-14 | Pinto Shelly | Buy | 15 000 | Common Stock |
2024-02-14 | Pinto Shelly | Buy | 35 000 | Employee Stock Option (right to buy) |
2024-02-14 | Garcia Peter S | Buy | 25 000 | Common Stock |
2024-02-14 | Garcia Peter S | Buy | 80 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
95.48 |
Last 97 transactions |
Buy: 3 568 851 | Sell: 526 117 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $11.15 (-2.28% ) |
Volume | 1.052 mill |
Avg. Vol. | 0.367 mill |
% of Avg. Vol | 286.63 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $13.99 | N/A | Active |
---|
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.